Radiation for Chemo-Sensitization: A Phase II Trial of Cetuximab and Docetaxel With Low-Dose Fractionated Radiation for Recurrent Unresectable Locally Advanced Head and Neck Carcinoma

Vivek N. Patel, MD, Felix M. Chinea, MD, Deukwoo Kwon, PhD, Gustavo Fernandez, MD, Hanmath J Neboori, MD, Michael A. Samuels, MD, Laura M. Freedman, MD, Nagy M. Elsayad, Donald Weed, MD, Elizabeth Franzmann, MD, Chukwuemeka V. Ikpeazu, MD, PhD, Matthew C. Abramowitz, MD
Published: Sunday, Mar 19, 2017
Vivek N. Patel, MD
Vivek N. Patel, MD
 

EXPERT'S PERSPECTIVE:

E. Ronald Hale,
MD, MPH

E. Ronald Hale, MD, MPH

 
Why is this article contemporary?

Despite great strides forward in the organ preservation treatment of head and neck cancer, recurrent disease in the inoperable patient afflicted with squamous cell carcinoma of the head and neck (SCCHN) often remains challenging. Re-excision is usually limited by radiation effect of prior treatment, or a history of a prior resection. For these patients, systemic therapy, re-irradiation, and other supportive care are often the only available options.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: How Can We Optimize Outcomes in Head and Neck Cancers with Immunotherapeutic Strategies?Oct 31, 20191.5
Publication Bottom Border
Border Publication
x